Unknown

Dataset Information

0

Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children.


ABSTRACT: Live-attenuated influenza vaccine (LAIV) was licensed for prophylaxis of children 2-17 years old in Europe in 2012 and is administered as a nasal spray. Live-attenuated influenza vaccine induces both mucosal and systemic antibodies and systemic T-cell responses. Tonsils are the lymph nodes serving the upper respiratory tract, acting as both induction and effector site for mucosal immunity. Here, we have studied the early tonsillar T-cell responses induced in children after LAIV. Thirty-nine children were immunized with trivalent LAIV (containing A/H1N1, A/H3N2, and B viruses) at days 3, 7, and 14 before tonsillectomy. Nonvaccinated controls were included for comparison. Tonsils and peripheral blood (pre- and postvaccination) were collected to study T-cell responses. Tonsillar and systemic T-cell responses differed between influenza strains, and both were found against H3N2 and B viruses, whereas only systemic responses were observed against A/H1N1. A significant increase in cross-reactive tonsillar CD8+ T cells recognizing conserved epitopes from a broad range of seasonal and pandemic viruses occurred at day 14. Tonsillar T cells showed significant cytokine responses (Th1, Th2, and granulocyte-macrophage colony-stimulating factor). Our findings support the use of LAIV in children to elicit broadly cross-reactive T cells, which are not induced by traditional inactivated influenza vaccines and may provide protection to novel virus strains.

SUBMITTER: Mohn KG 

PROVIDER: S-EPMC7137893 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children.

Mohn K G-I KG   Brokstad K A KA   Islam S S   Oftung F F   Tøndel C C   Aarstad H J HJ   Cox R J RJ  

The Journal of infectious diseases 20200401 9


<h4>Background</h4>Live-attenuated influenza vaccine (LAIV) was licensed for prophylaxis of children 2-17 years old in Europe in 2012 and is administered as a nasal spray. Live-attenuated influenza vaccine induces both mucosal and systemic antibodies and systemic T-cell responses. Tonsils are the lymph nodes serving the upper respiratory tract, acting as both induction and effector site for mucosal immunity.<h4>Methods</h4>Here, we have studied the early tonsillar T-cell responses induced in chi  ...[more]

Similar Datasets

| S-EPMC4978372 | biostudies-literature
| S-EPMC4200073 | biostudies-literature
| S-EPMC8395915 | biostudies-literature
| S-EPMC5461427 | biostudies-literature
| S-EPMC4451682 | biostudies-literature
| S-EPMC10821225 | biostudies-literature
2017-09-05 | E-MTAB-4669 | biostudies-arrayexpress
| S-EPMC4246941 | biostudies-literature
| S-EPMC4407761 | biostudies-literature
| S-EPMC4514187 | biostudies-literature